Gaithersburg’s Novavax Inc. (NASDAQ: NVAX) has been in the spotlight since January for its work on a novel coronavirus vaccine, but it will need more support to advance the program at the necessary speed, its head of research said Monday.
The Maryland biotech is now moving toward a phase 1 clinical trial after pulling in support from local players.
Two months after it started, “we’re very clearly confident that we can make a vaccine,” said Dr. Gregory Glenn, its president of research and development.